Allergan Press Releases

都柏林, 2018年2月6日/PRNewswire/ -- Allergan Plc, (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the first of two pivotal phase 3 clinical trials evaluating the efficacy, safety and tolerability of orally administered ubrogepant 50 mg and ubrogepant 100 mg compared to placebo in a single migraine attack in adults.

都柏林, Feb. 5, 2018/PRNewswire/ -- Allergan Plc(NYSE: AGN) a leading global biopharmaceutical company, today announced that Matthew M. Walshhas been appointed Executive Vice President and Chief Financial Officer. He will formally join Allerganlater this month following a transition period from his current role as Executive Vice President, Chief Financial Officer at Catalent，Inc。

都柏林, Feb. 1, 2018/PRNewswire/ -- Allergan Plc(NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Food and Drug Administration( FDA）已批准 Allergan'ssupplemental New Drug Application (sNDA) to expand the approved use of AVYCAZ^®(ceftazidime and avibactam) to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms:Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzaein patients 18 years of age or older. This expanded use is based on positive results from a pivotal Phase 3 study evaluating the efficacy and safety of AVYCAZ for the treatment of adult patients with HABP/VABP. The sNDA received priority review from FDA基于HABP/VABP指示的合格传染病产品（QIDP）名称。

都柏林, Jan. 31, 2018/PRNewswire/ -- Allergan Plc(NYSE:AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer 威廉·梅里（William Meury）和 Chief Research和Development Officer David Nicholsonwill present at the Leerink Partners7^thAnnual Global Healthcare Conference in 纽约，纽约。演讲将开始 10:00 a.m. Eastern Time在 Thursday, February 15, 2018。

都柏林, Jan. 31, 2018/PRNewswire/ -- Allergan Plc(NYSE: AGN) today launches a new multi-channel direct-to-consumer campaign for CoolSculpting, titled "Not Cool vs. Cool," which includes a national traditional and digital media effort and two new brand ambassadors: figure skating superstar 约翰尼·威尔（Johnny Weir）和精英高尔夫球手 Ian Poulter。CoolSculpting is the only FDA- 透明的，非手术的治疗，以冻结顽固的脂肪。

都柏林, 2018年1月8日/PRNewswire/ -- Allergan Plc（NYSE：AGN），一家领先的全球制药公司，正在第36届年度提供2018年初步财务前景和其他财务更新 J.P. Morgan Healthcare Conferencein 旧金山today. Commenting on the Company's 2018 outlook, Allergan董事长兼首席执行官 Brent Saunders说：“尽管我们面临2018年排他性收入的损失，但 Allergan在近期和长期内释放价值的稳固位置。我们的信心是由企业持久的增长前景，我们正在为组织的统治尺寸，我们的治疗领域领导，深层和高潜力的管道以及强大的现金流量和资产负债表所付出的努力。这些要素在一起为 Allergan在2018年及以后为股东带来价值。”

都柏林, 2018年1月8日/PRNewswire/ -- Allergan Plc（NYSE：AGN）今天宣布打算发布2017年第四季度和全年财务业绩 Tuesday, February 6, 2018, prior to the open of U.S. Financial Markets. Allerganwill host a conference call and webcast at 8:30 a.m. Eastern Time在 Tuesday, February 6, 2018to discuss its financial results. The dial-in number to access the call is U.S./ Canada（877）251-7980，国际（706）643-1573，会议ID为67779395。